Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination
Chi, Xin-Zi ; Kim, Jiyeon ; Lee, Yong-Hee ; Lee, Jung-Won ; Lee, Kyeong-Sook ; Wee, Hee-Jun ; Kim, Wun-Jae ; Park, Woo-Yoon ; Oh, Byung-Chul ; Stein, Gary S. ... show 3 more
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
Blotting, Western
Cell Transformation, Neoplastic
Cells, Cultured
Core Binding Factor Alpha 3 Subunit
inhibitors
Gene Expression Regulation, Neoplastic
Humans
Immunoprecipitation
Kidney
Mutation
Proto-Oncogene Proteins c-mdm2
RNA, Small Interfering
Transcription, Genetic
Transcriptional Activation
Transfection
Tumor Suppressor Protein p14ARF
Tumor Suppressor Protein p53
Ubiquitination
Ubiquitins
ras Proteins
Cell Biology
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
The p14(ARF)-MDM2-p53 pathway constitutes an effective mechanism for protecting cells from oncogenic stimuli such as activated Ras and Myc. Importantly, Ras activation induces p14(ARF) and often occurs earlier than p53 inactivation during cancer development. Here, we show that RUNX3, a tumor suppressor in various tumors including stomach, bladder, colon, and lung, is stabilized by Ras activation through the p14(ARF)-MDM2 signaling pathway. RUNX3 directly binds MDM2 through its Runt-related DNA-binding domain. MDM2 blocks RUNX3 transcriptional activity by interacting with RUNX3 through an acidic domain adjacent to the p53-binding domain of MDM2 and ubiquitinates RUNX3 on key lysine residues to mediate nuclear export and proteasomal degradation. Our data indicate that the lineage-specific tumor suppressor RUNX3 and the ubiquitous p53 protein are both principal responders of the p14(ARF)-MDM2 cell surveillance pathway that prevents pathologic consequences of abnormal oncogene activation.
Source
Cancer Res. 2009 Oct 15;69(20):8111-9. Epub 2009 Oct 6. Link to article on publisher's site